EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease.
OBJECTIVE Much of the available real-world evidence on the gut-selective α4β7 integrin antibody vedolizumab comes from patients with repeated failure of anti-tumour necrosis factor-α (anti-TNFα) agents and other treatments. The EVOLVE-IBERIA study is aimed to generate additional real-world evidence for vedolizumab and...